Genotoxic action of cycloplatam, a new platinum antitumor drug, on mammalian cells in vivo and in vitro

Chemotherapy

Volumn 49, Issue 3, 2003, Pages 132-137

  Nersesyan, Armen ^a   Perrone, Emanuela ^b   Roggieri, Paola ^b   Bolognesi, Claudia ^b  

^a Department of Radiation Oncology   (Armenia)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Antineoplastic agent; Cisplatin; Cycloplatam; Micronucleus assay; Mutagenicity; Organoplatinum compounds

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; CYCLOPLATAM; MITOMYCIN; MOSMEDPREPARATI; PLATINUM DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; BONE MARROW TOXICITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FEMALE; GENOTOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE; MALE; MAMMAL CELL; MICRONUCLEUS; MOUSE; MUTAGENIC ACTIVITY; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE MARROW CELLS; CELL CULTURE TECHNIQUES; CISPLATIN; DNA DAMAGE; FEMALE; HUMANS; LYMPHOCYTES; MALE; MICE; MICRONUCLEUS TESTS; MUTAGENICITY TESTS; ORGANOPLATINUM COMPOUNDS;

EID: 0038308368     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000070619     Document Type: Article

References (40)

1. Presnov MA, Konovalova AL: Cycloplatam and oxoplatin - the new antitumor platinum compounds of the second generation. Arch Geschwulstforsch 1980;1:43-49.
2. Drees M, Dengler WM, Hendriks HR, Kelland LR, Fiebig HH: Cycloplatam: A novel platinum compound exhibiting a different spectrum of anti-tumour activity to cisplatin. Eur J Cancer 1995;31A:356-361.
3. Konovalova AL; Cheltsov PA, Stetsenko AI, Syrkin AB: Antitumor activity of new platinum complexes. 7th NCI-EORTC Symp on New Drugs in Cancer Therapy, Amsterdam, 1992, pp 92-93.
4. Bakhteeva VT, Fok EM, Lavrova EA: Comparative study of the action of antineoplastic platinum compounds with varying nephrotoxic effects. Vopr Med Khim 1996;42:301-306.
5. Natochin IV, Beznik LV, Brovtsin VK, Ivanov VB, Miazina EM, Chel'tsov PA, Shakhmatova EI: Characteristics of the action of cisplatin and cycloplatam on the rat kidney. Biull Eksp Biol Med 1989;108:52-54.
6. Bagrova SG: Results of phase II clinical trial of cycloplatam in refractory solid tumors. Vopr Oncol 2001;47:752-756.
7. Matveev BP, Gorbunova VA, Smirnova NB, Zhumagazin ZD, Bukharkin BV, Orel NF: Cycloplatam in the treatment of patients with disseminated prostatic cancer. Urol Nefrol 1996;3:34-36.
8. Perrin LC, Cullinane C, McFadyen WD, Phillips DR: Sequence specificity and reactivity of the binding of platinum complexes to DNA. Anticancer Drug Des 1999;14:243-252.
9. Butour JL, Wimmer S, Wimmer F, Castan P: Palladium (II) compounds with potential anti-tumour properties and their platinum analogues: A comparative study of the reaction of some orotic acid derivatives with DNA in vitro. Chem Biol Interact 1997;104:165-178.
10. Dederer L, Lankin VZ, Konovalova AL, Gorbacheva LB: Biochemical mechanisms of resistance to a new antineoplastic agent amin(cyclopeptidylamin)-S-(-)malatoplatinum (II) (cycloplatam). Biokhimiia 1995;60:602-609.
11. Khabarov SV, Getasimova GK: Effect of anti-tumor agents cisplatin and cycloplatam on membrane protein kinase C activity in murine T-lymphocytes. Biokhimiia 1996;61:1866-1873.
12. Sanderson BJS, Ferguson L, Denny WA: Mutagenic and carcinogenic properties of platinum-based anticancer drugs. Mutat Res 1996;355:59-68.
13. Gebel T, Lantzsch H, Plesow K, Dunkelberg H: Genotoxicity of platinum and palladium compounds in human and bacterial cells. Mutat Res 1997;389:183-190.
14. Edelweiss MI, Trachtenberg A, Pinheiro EX, da Silva J, Riegel M, Lizardo-Daudt HM, Mattevi MS: Clastogenic effect of cisplatin on Wistar rat bone marrow cells. Braz J Med Biol Res 1995;28:679-683.
15. Mazur L, Czyzewska A, Augustynek A: WR-2721: Inhibitor of cisplatin-induced micronuclei. Teratog Carcinog Mutagen 2000;20:349-356.
16. Antuñes LM, Francescato HD, Darin JD, de Lourdes P, Bianchi M: Effects of selenium pretreatment on cisplatin-induced chromosome aberrations in Wistar rats. Teratog Carcinog Mutagen 2000;20:341-348.
17. Slavutsky I, Campos E, Cid MG, Larripa I: Micronuclei induction by carboplatin in human lymphocyte subpopulations. Anticancer Drugs 1995;6:758-762.
18. Gorbacheva LB, Valieva SV, Makhova EF, Moshkovskaya EI, Sokolova IS, Tikhomirov AG, Dederer LI: The new antitumor drug cycloplatam: Cytotoxicity and DNA interstrand cross-linking. Antibiot Khimioter 1999;44:9-12.
19. Tikhomirov AG, Sokolova IS, Dederer LY, Gorbacheva LB: Effect of the novel antineoplastic agent cycloplatam on the structure and synthesis of DNA. Bul Eksp Biol Med 1998;125:197-199.
20. Ptitsyn LR, Riazanova LA, Ivanov VB: Use of Escherichia coli recF mutant strains for analyzing the genotoxicity of complex platinum compounds. Genetika 1997;33:1020-1024.
21. Schmid W: The micronucleus test. Mutat Res 1975;31:9-15.
22. Tinwell H, Ashby J: Comparison of acridine orange and Giemsa stains in several mouse bone marrow micronucleus assays - including a triple dose study. Mutagenesis 1989;4:476-481.
23. Nersessian AK, Mouradian RE: The influence of immunization with tularemia live vaccine on the clastogenic action of cyclophosphamide in mice. Mutat Res 1996;356:225-228.
24. O'Neill CF, Orr RM, Kelland LR, Harrap KR: Comparison of platinum (Pt) binding to DNA and removal of total Pt adducts and interstrand crosslinks in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin. Cell Pharmacol 1995;2:1-7.
25. Barry MA, Behnke CA, Eastman A: Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem Pharmacol 1990;40:2353-2362.
26. Borner MM, Joncourt F, Hotz MA: Similarity of apoptosis induction by 2-chlorodeoxyadenosine and cisplatin in human mononuclear blood cells. Br J Cancer 1997;76:1448-1454.
27. Mesner PW, Budihardjio II, Kaufmann SH: Chemotherapy-induced apoptosis. Adv Pharmacol 1997;41:461-499.
28. Lepre CA, Lippard SJ: Interaction of platinum antitumor compounds with DNA; in Eckstein F, Lilley DMJ (eds): Nucleic Acids and Molecular Biology. Heidelberg, Springer, 1990, vol 4, pp 29-38.
29. Jackson MA, Stack HF, Waters MD: Genetic activity profiles of anticancer drugs. Mutat Res 1996;355:171-208.
30. Ferguson LR, Pearson AE: The clinical use of mutagenic anticancer drugs. Mutat Res 1996;355:1-12.
31. Zwelling LA, Bradely MO, Sharkey NA, Anderson T, Kohn KW: Mutagenicity, cytotoxicity and DNA crosslinking in V79 Chinese hamster cells treated with cis and trans Pt(II) diamminedichloride. Mutat Res 1979;67:271-280.
32. Bradley LJ, Yarema KJ, Lippard SJ, Essigmann JM: Mutagenicity and genotoxicity of the major DNA adduct of the antitumor drug cis-diamminedichloroplatinum (II). Biochemistry 1993;32:982-988.
33. Yarema KJ, Wilson JM, Lippard SJ, Essigmann JM: Effects of DNA adduct structure and distribution on the mutagenicity and genotoxicity of two platinum anticancer drugs. J Mol Biol 1994;236:1034-1048.
34. Wiencke JK, Cervenka J, Paulus H: Mutagenic activity of anticancer agent cis-dichlorodiammine platinum-II. Mutat Res 1979;68:69-77.
35. Osanto S, Thijssen JCP, Woldering WM, Van Rijn JLS, Natarajan AT, Tates AD: Increased frequency of chromosomal damage in peripheral blood lymphocytes up to nine years following curative chemotherapy of patients with testicular carcinoma. Environ Mol Mutagen 1991;17:71-78.
36. Choudhury RC, Jagdale MB, Misra S: Cytogenetic toxicity of cisplatin in bone marrow cells of Swiss mice. J Chemother 2000;12:173-182.
37. Garriott ML, Phelps JB, Hoffman WP: A protocol for the in vitro micronucleus test. I. Contributions to the development of a protocol suitable for regulatory submissions from an examination of 16 chemicals with different mechanisms of action and different levels of activity. Mutat Res 2002;517:123-134.
38. Shada FF, Koziol J: Induced genome instability as a potential screening test for cancer susceptibility? Med Hypotheses 2000;55:69-72.
39. Maluf SW, Erdtmann B: Genomic instability in Down syndrome and Fanconi anemia assessed by micronucleus analysis in single-cell gel electrophoresis. Cancer Genet Cytogenet 2001;124:71-75.
40. Trenz K, Rothfuss A, Schutz P, Speit G: Mutagen sensitivity of peripheral blood for women carrying a BRCA1 or BRCA2 mutation. Mutat Res 2002;500:89-96.